Podcast: What Does The Pfizer/Seagen Merger Mean For M&A In 2023?

A Discussion Of Current Deal Trends

 
• By Joseph Haas

Scrip overviews biopharma deal-making in 2022 and discusses the Pfizer/Seagen merger and its ramifications for the remainder of 2023, with EF Hutton analyst Mike King and Mintz attorney Matt Gardella.

M&A
Will the Pfizer/Seagen deal mean a wave of larger M&A in biopharma? • Source: Shutterstock

More from Deals

More from Business